Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
Status:
Unknown status
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish whether RA patients with moderate to severe disease
activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy
with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.